Mostrando 3 resultados de: 3
Nimotuzumab in combination with radiotherapy in high grade glioma patients: A single institution experience
ArticleAbstract: Nimotuzumab, a humanized antibody targeting epidermal growth factor receptor, has potent anti-prolifPalabras claves:Anaplastic astrocytoma, glioblastoma multiforme, High grade glioma, Monoclonal antibody, nimotuzumab, RadiotherapyAutores:Alert J., Chon I., Jorrín E., Luaces P.L.o., Marinello J.J.u., Miranda N., Solomón M.T.e., Tania CrombetFuentes:scopusNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
ArticleAbstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elePalabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapyAutores:Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.Fuentes:scopusRadiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial
ArticleAbstract: BACKGROUND: The prognosis of patients bearing high grade glioma remains dismal. Epidermal Growth FacPalabras claves:Autores:Alert J., Bach F., Ballesteros J., Catala M., de-Castro N., Domíngez R., Figueredo J., Griego M.G.o., Luaces P.L.o., Marinello J.J.u., Martell J.A.n., Quintanal N., Salva S., Selva J.C.é., Solomón M.T.e., Tania Crombet, Toledo C., Vaquer J.Fuentes:scopus